We recently published a list of 10 Firms Defy Market Slump, Record Double-Digit Gains Last Week. In this article, we are ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

We recently published a list of 10 Firms Buck Thursday’s Market Bloodbath. In this article, we are going to take a look at ...

The UK's new car market experienced a 12.4% increase in March 2025, reaching 357,103 units, according to the Society of Motor ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

The electric vehicle revolution continues to gain momentum with battery electric cars (BEVs) on UK roads surpassing one ...

Shares of Summit Therapeutics (NASDAQ:SMMT) traded higher for the second straight session on Thursday after Cantor Fitzgerald said that an earlier-than-expected warrant exercise by the company’s ...

Summit Therapeutics Inc.’s SMMT share price has surged by 10.04%, which has investors questioning if this is right time to ...

Summit Therapeutics (SMMT – Research Report) received a Buy rating and price target from Cantor Fitzgerald analyst Eric Schmidt FCA today.

Corebridge Financial Inc. decreased its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 2.3% in the fourth quarter, according to its most recent filing with the Securities and ...